Formulation design and characterization of osmotically controlled tablet of Ramipril

B. Nayak, P. Ellaiah, S. Sethy, M. Nayak, Subham Sourajit
{"title":"Formulation design and characterization of osmotically controlled tablet of Ramipril","authors":"B. Nayak, P. Ellaiah, S. Sethy, M. Nayak, Subham Sourajit","doi":"10.26510/2394-0859.PBE.2017.01","DOIUrl":null,"url":null,"abstract":"Objective: Ramipril is a long-acting angiotensin-converting enzyme inhibitor. The study aimed to design, formulate and evaluate the oral osmotic drug delivery dosage form of an anti-hypertensive drug, ramipril. Methods: The tablet was formulated using ramipril and different polymers like PVP- K30 and Ethyl cellulose. The microcrystalline cellulose (MCC - diluent), Potassium chloride, Mannitol (osmogen) and Magnesium stearate (lubricant) were used in all the formulations. All the tablets were manufactured by wet granulation method followed by film coating. Compatibility of the drug with excipients was determined by FT-IR spectral analysis. The granules were evaluated for bulk density, Carr’s index and Hausner’s ration to determine flow properties. The prepared compressed and coated tablets were evaluated for weight variation, thickness, hardness, friability, and drug content and in vitro drug release and release kinetic studies. Results: The FT-IR study revealed that drug was compatible with excipients.  The flow properties of granules of most formulation were excellent. All osmotic tablet formulations had good tablet physiochemical properties as per Pharmacopeia. The drug content of all tablet batches was satisfactory. The in vitro drug release study revealed that the formulation F7 containing 100 mg of ethyl cellulose release 100% of drug in 24 h with zero order release kinetics. Conclusions: Ramipril osmotic tablet could be used for safe management of hypertension with greater novelty.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical and Biological Evaluations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26510/2394-0859.PBE.2017.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Ramipril is a long-acting angiotensin-converting enzyme inhibitor. The study aimed to design, formulate and evaluate the oral osmotic drug delivery dosage form of an anti-hypertensive drug, ramipril. Methods: The tablet was formulated using ramipril and different polymers like PVP- K30 and Ethyl cellulose. The microcrystalline cellulose (MCC - diluent), Potassium chloride, Mannitol (osmogen) and Magnesium stearate (lubricant) were used in all the formulations. All the tablets were manufactured by wet granulation method followed by film coating. Compatibility of the drug with excipients was determined by FT-IR spectral analysis. The granules were evaluated for bulk density, Carr’s index and Hausner’s ration to determine flow properties. The prepared compressed and coated tablets were evaluated for weight variation, thickness, hardness, friability, and drug content and in vitro drug release and release kinetic studies. Results: The FT-IR study revealed that drug was compatible with excipients.  The flow properties of granules of most formulation were excellent. All osmotic tablet formulations had good tablet physiochemical properties as per Pharmacopeia. The drug content of all tablet batches was satisfactory. The in vitro drug release study revealed that the formulation F7 containing 100 mg of ethyl cellulose release 100% of drug in 24 h with zero order release kinetics. Conclusions: Ramipril osmotic tablet could be used for safe management of hypertension with greater novelty.
雷米普利渗透控释片的配方设计与表征
目的:雷米普利是一种长效血管紧张素转换酶抑制剂。本研究旨在设计、配制和评价抗高血压药物雷米普利的口服渗透给药剂型。方法:采用雷米普利与PVP- K30、乙基纤维素等不同聚合物配制该片。所有配方均采用微晶纤维素(MCC -稀释剂)、氯化钾、甘露醇(渗透剂)和硬脂酸镁(润滑剂)。所有片剂均采用湿造粒-膜包衣法制备。用红外光谱法测定了药物与辅料的配伍性。对颗粒的容重、卡尔指数和豪斯纳比进行了评估,以确定颗粒的流动特性。对所制备的压缩包衣片进行重量变化、厚度、硬度、脆性、药物含量的评价,并进行体外释药动力学研究。结果:傅里叶变换红外光谱(FT-IR)显示药物与辅料配伍良好。大多数配方的颗粒的流动性能都很好。所有渗透片制剂均按药典规定具有良好的片剂理化性质。各批次片剂的药物含量均令人满意。体外释药研究表明,含有100 mg乙基纤维素的F7制剂在24 h内释药100%,具有零级释药动力学。结论:雷米普利渗透片可用于高血压的安全治疗,具有较大的新颖性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信